Amarantus Bioscience Holdings Inc (AMBS)

[Goldstrike]

"During 2000-09 the average (mean) orphan product approval period was one year compared to 1.5 years for non-orphan products." http://www.clinuvel.com/en/blog/pharmadev/new-drug-approval-rates/

Link to story: http://globenewswire.com/news-release/2014/12/19/692929/10113053/en/Amarantus-Submits-Orphan-Drug-Designation-Application-to-US-FDA-for-Treatment-of-Retinal-Artery-Occlusion-With-Product-Candidate-MANF.html